胰腺晚期常用放化疗药物治疗方案（Advanced chemotherapy and radiotherapy regimen for advanced pancreas）.docVIP

胰腺晚期常用放化疗药物治疗方案（Advanced chemotherapy and radiotherapy regimen for advanced pancreas） Advanced chemotherapy and radiotherapy regimen for advanced pancreas Compared with lung cancer, liver cancer and other malignant tumors, pancreatic cancer treatment program is less, the clinical treatment of choice of drugs is also less, the surgical resection of pancreatic cancer patients with surgery based, in this case is not repeated. Chemotherapy and radiotherapy remain the most common treatment for advanced pancreatic cancer. Chemotherapy: The purpose of chemotherapy is to prolong life and improve the quality of life: 1. adjuvant chemotherapy is now evidence that adjuvant chemotherapy for pancreatic cancer prolongs survival. The commonly used chemotherapy drugs were gemcitabine 1000mg/m2 intravenous drip for 30 minutes, 1 times a week, 2 weeks for 1 weeks, 21 days for one cycle, a total of 4 cycles (12 weeks). Pay attention to matters of adjuvant chemotherapy adjuvant chemotherapy of pancreatic cancer should begin in January after radical surgery; adjuvant chemotherapy before including abdominal pelvic enhanced CT scan, chest side phase, peripheral blood, liver and kidney function, electrocardiogram and tumor markers CEA, CA19-9 etc.. Chemotherapy to observe and treat the adverse reactions of chemotherapy in time. 2. palliative chemotherapy Adjuvant chemotherapy Radiation therapy: Radiation therapy is mainly used in the treatment of unresectable locally advanced pancreatic cancer, combined treatment of residual or recurrent tumors, and palliative palliation of advanced pancreatic cancer. 1. principles of radiotherapy for pancreatic cancer (1) using 5- fluorouracil or gemcitabine based synchronous radiotherapy. (2) local advanced pancreatic cancer without distant metastasis should be performed. If the patient is in general condition, synchronous radiotherapy should be given to obtain the opportunity of surgical resection or prolong the survival time of the patient. (3) non rad